Organic compounds

Abstract

Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

1 - 6 . (canceled) 
     
     
         7 . A method of treating any of the following conditions: Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, drug-induced movement disorders, depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorder, narcolepsy, cognitive impairment, cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, drug addiction, cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, sexual dysfunction, asthma, chronic obstructive pulmonary disease, allergic rhinitis, autoimmune diseases, inflammatory diseases, female sexual dysfunction, exercise amenorrhoea, anovulation, menopause, menopausal symptoms, hypothyroidism, pre-menstrual syndrome, premature labor, infertility, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, multiple sclerosis, prostate enlargement, prostate cancer, hypothyroidism, estrogen-induced endometrial hyperplasia or carcinoma, glaucoma, elevated intraocular pressure, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, and traumatic brain injury, and/or any disease or condition characterized by low levels of cAMP and/or cGMP (or inhibition of cAMP and/or cGMP signaling pathways) in cells expressing PDE1, and/or by reduced dopamine D1 receptor signaling activity, and/or any disease or condition that may be ameliorated by the enhancement of progesterone signaling, comprising administering an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 (vi) n is 1, 2, 3, or 4, 
 
       in free or pharmaceutically acceptable salt form, to a patient in need thereof. 
     
     
         8 . The method of  claim 7 , wherein the condition is Parkinson's disease. 
     
     
         9 . The method of  claim 7 , wherein the condition is cognitive impairment. 
     
     
         10 . The method of  claim 7 , wherein the condition is cognitive impairment of schizophrenia. 
     
     
         11 . The method of  claim 7 , wherein the condition is narcolepsy. 
     
     
         12 . The method of  claim 11  further comprising administering one or more compounds selected from central nervous system stimulants, modafinil, antidepressants, and gamma hydroxybutyrate, to a patient in need thereof. 
     
     
         13 . The method of  claim 7 , wherein the condition is female sexual dysfunction. 
     
     
         14 . The method of  claim 13 , further comprising administering one or more compounds selected from estradiol, estriol, estradiol esters, progesterone and progestins, to a patient in need thereof. 
     
     
         15 . A method for the treatment of glaucoma or elevated intraocular pressure comprising topical administration of an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 (vi) n is 1, 2, 3, or 4, 
 
       
       in free or pharmaceutically acceptable salt form, in an ophthalmically compatible carrier to the eye of a patient in need thereof. 
     
     
         16 . A method for the treatment of traumatic brain injury comprising administering an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 
         (vi) n is 1, 2, 3, or 4, 
       
       in free or pharmaceutically acceptable salt form, to a patient in need thereof. 
     
     
         17 - 30 . (canceled) 
     
     
         31 . The method of  claim 7 , wherein the compound of Formula 1 is a compound of Formula I(i): 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen; unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 (vi) n is 1, 2, 3, or 4, 
 
       in free or salt form. 
     
     
         32 . The method according to  claim 7 , wherein the compound is a compound of Formula I(H): 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; and 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen; unsubstituted phenyl; phenyl substituted with one or more halogen phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen, 
 
       in free or salt form. 
     
     
         33 . The method according to  claim 32 , wherein
 (i) R 1  is C 1-4  alkyl;   (ii) R 2  and R 3  are independently C 1-6  alkyl;   (iii) R 4  is H;   (iv) R 5  is aryl substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl;   (v) R 6  is aryl substituted with one or more groups independently selected from C 1-6  alkyl; halogen; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and   (vi) R 7  is H,   in free or salt form.   
     
     
         34 . The method according to  claim 32 , wherein the compound is selected from 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         35 . The method according to  claim 7 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         36 . The method according to  claim 7 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         37 . The method according to  claim 7 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         38 . The method according to  claim 7 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         39 . A method of treating any of the following conditions: Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, drug-induced movement disorders, depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorder, narcolepsy, cognitive impairment, cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, drug addiction, cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, sexual dysfunction, asthma, chronic obstructive pulmonary disease, allergic rhinitis, autoimmune diseases, inflammatory diseases, female sexual dysfunction, exercise amenorrhoea, anovulation, menopause, menopausal symptoms, hypothyroidism, pre-menstrual syndrome, premature labor, infertility, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, multiple sclerosis, prostate enlargement, prostate cancer, hypothyroidism, estrogen-induced endometrial hyperplasia or carcinoma, glaucoma, elevated intraocular pressure, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, traumatic brain injury, comprising administering a pharmaceutical composition comprising an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 (vi) n is 1, 2, 3, or 4, 
 
       in free or pharmaceutically acceptable salt form, in admixture with a pharmaceutically acceptable diluent or carrier, to a patient in need thereof. 
     
     
         40 . The method of  claim 39 , wherein the compound of Formula 1 is a compound of Formula I(i): 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen; 
 unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and 
 (vi) n is 1, 2, 3, or 4, 
 
       in free or salt form. 
     
     
         41 . The method of  claim 39 , wherein the compound is a compound of Formula I(ii): 
       
         
           
           
               
               
           
         
       
       wherein
 (i) R 1  is H or C 1-4  alkyl; 
 (ii) R 2  and R 3  are independently H or C 1-6  alkyl; 
 (iii) R 4  is H or C 1-4  alkyl; 
 (iv) R 5  is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl; and 
 (v) R 6  and R 7  are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6  alkyl and halogen; unsubstituted phenyl; phenyl substituted with one or more halogen phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen, 
 
       in free or salt form. 
     
     
         42 . The method according to  claim 41 , wherein
 (i) R 1  is C 1-4  alkyl;   (ii) R 2  and R 3  are independently C 1-6  alkyl;   (iii) R 4  is H;   (iv) R 5  is aryl substituted with one or more groups independently selected from —C(═O)—C 1-6  alkyl and C 1-6 -hydroxyalkyl;   (v) R 6  is aryl substituted with one or more groups independently selected from C 1-6  alkyl; halogen; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6  alkyl and one or more halogen; or phenyl substituted with one C 1-6  alkyl and one halogen; and   (vi) R 7  is H,   in free or salt form.   
     
     
         43 . The method according to  claim 39 , wherein the compound is selected from 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         44 . The method according to  claim 39 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         45 . The method according to  claim 39 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         46 . The method according to  claim 39 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form. 
     
     
         47 . The method according to  claim 39 , wherein the compound of Formula I is 
       
         
           
           
               
               
           
         
       
       in free or salt form.